Witnesses Seek 15% Boost For NCI In 1998 as First Step to 100% Raise Over 5 Years
In Brief: visco Named to Cancer Policy Board; Foundation Pledges $6.5 Million to Karmanos
In This Issue: Congressional Testimony On NIH, NCI Appropriations, FDA Reform
Patient Advocates; NBCC Delivers 2.6M Signatures, demands 2.6Billion
NIH director; Targets Increases Favor Established Researchers
Pharmaceutical Industry: IVAX Official Broder Objects To Orphan Drug Policies of FDA
National Academy elects New Members
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on - California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power - Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53
Shokat was named 2026 Stephenson Global Prize winner - Iowa’s “cancer crisis” emerges as a top issue on the campaign trail
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
